Select Page

Home / News / BioBlast® / Biosimilar Deals 2021

EXPLORE OUR

Biosimilars Deals 2021

Explore our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date. Alternatively, review our weekly BioBlast updates below.

New Indication Alert: Celltrion’s Biosimilar Tocilizumab FDA-Approved for COVID-19 Treatment in Paediatric Patients

On 7 October 2026, Celltrion announced that the FDA has approved an additional indication for its IV formulation of Avtozma® (tocilizumab), biosimilar to Roche/Genentech’s Actemra®, for the treatment of COVID-19 in paediatric patients aged 2 years and older.  This expands the previous US approved indications for Avtozma®, which included COVID-19 in adults.

Both the intravenous and subcutaneous formulations of Avtozma® were first approved in the US in January 2025, with the IV formulation launched in October 2025.  In August 2025, the FDA approved an additional indication for the IV formulation for the treatment of cytokine release syndrome.  In December 2025, Celltrion secured reimbursement coverage for Avtozma® IV in the US, with patient reimbursement available from January 2026.

Biogen/Bio-Thera’s Tofidence®/BAT1806 (tocilizumab-bavi) was the first US approved tocilizumab biosimilar (IV formulation approved September 2023; launched May 2024), followed by Fresenius Kabi’s Tyenne® (tocilizumab-aazg) (March 2024; IV formulation launched April 2024; SC formulation launched July 2024).

Celltrion’s Avtozma® was the first tocilizumab biosimilar to be approved in Korea in December 2024.  In the same month, Avtozma® received a positive recommendation by the EMA’s CHMP and subsequently gained European Commission approval in February 2025.  The biosimilar has also been granted marketing approval in other regions, including as the first tocilizumab biosimilar approved in Australia (May 2025), Japan (September 2022) and New Zealand (December 2025).  On 1 October 2026, Celltrion’s Avtozma® became the first tocilizumab biosimilar to be listed on Australia’s Schedule of Pharmaceutical Benefits, after being recommended for PBS-listing at the November 2025 PBAC meeting.

MSD’s Subcutaneous Keytruda® Blocked from Launch in 8 European Countries by Halozyme Injunction Win

On 7 October 2026, Halozyme Therapeutics announced that it has won an injunction from the specialised Dutch patent court of The Hague, preventing MSD from manufacturing, selling, importing and stockpiling Keytruda SC™ (pembrolizumab and berahyaluronidase alfa-pmph) in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands.

The Court ordered the injunction based on its finding that Halozyme’s patent, EP 297 622 (EP 622) is valid and infringed by MSD.  EP 622 relates to modified PH20 hyaluronidase polypeptides and compositions, which Halozyme claims allow for rapid subcutaneous administration of therapeutic drugs.

MSD’s subcutaneous pembrolizumab formulation uses Alteogen’s ALT-B4 technology, a recombinant human hyaluronidase enzyme platform (berahyaluronidase alfa) designed to convert intravenous (IV) drugs into subcutaneous formulations.  Under licensing terms with MSD, Alteogen obtains milestone payments and ongoing commercial royalties linked to Keytruda SC™ sales.  However, according to Korea Economic Daily, Alteogen expects little financial impact from the Dutch court ruling, with the outcome estimated to affect only 3% of Keytruda SC™’s global market.

The final injunction granted by the Dutch Court follows a ruling of the District Court of The Hague in July 2026 dismissing Halozyme’s application for a preliminary injunction to prevent MSD from marketing Keytruda SC™ in Denmark and Sweden pending the outcome of the substantive proceedings.

MSD and Halozyme are also in dispute elsewhere over patents to Halozyme’s MDASE™ subcutaneous delivery technology.  In December 2025, the Munich Regional Court granted a preliminary injunction, preventing MSD from distributing and offering for sale in Germany Keytruda SC™, based on a finding of the Court that there was imminent infringement of EP 622.

In April 2024, Halozyme sued MSD in the US, alleging that MSD’s subcutaneous pembrolizumab (Keytruda Qlex®) infringes 15 patents.  As of 7 October 2026, MSD had successfully invalidated claims of 9 of Halozyme’s US patents before the Patent Trial and Appeal Board (PTAB) and had a further 8 petitions pending before PTAB.

MSD’s subcutaneous pembrolizumab was approved in Europe in November 2025.  It has also been approved in the US as Keytruda Qlex™ (September 2025); in Canada (February 2026), Korea (May 2026, launched September 2026) and Australia (July 2026), as Keytruda SC™; and in Japan as Keyject™ (September 2026).

While there are no reports of biosimilar subcutaneous pembrolizumab development to date, there are multiple pembrolizumab (IV) biosimilars approved or in development.  For example, Samsung Bioepis and Celltrion each applied for Korean approval of their pembrolizumab biosimilars in August 2026 (SB27 and CT-P51, respectively).  In June 2026, Samsung Bioepis claimed to be the first developer of a pembrolizumab biosimilar to announce global phase 3 trial results.  Amgen also confirmed on 15 September 2026 that its Keytruda® biosimilar has successfully completed clinical trials with an FDA submission likely later this year.  Formycon announced successful Phase 1 results in February 2026, with its US commercialisation partner, Zydus, expressing optimism that it is well-placed to file the first BLA in the US for biosimilar pembrolizumab.

First Omalizumab Biosimilar Enters US Market with Launch of Celltrion’s Omlyclo®

On 6 October 2026, Celltrion announced the US launch of Omlyclo®, biosimilar to Genentech/Novartis’ Xolair® (omalizumab).  Omlyclo® is the first omalizumab biosimilar on the US market and is available in three dosage forms: 75 mg, 150 mg and 300 mg.

Omlyclo® was first approved in the US in March 2025, in 75 mg/0.5ml and 150mg/ml PFS forms, with full interchangeable status.  The 300 mg formulation was FDA approved in December 2025.

The European launch of Omlyclo® in 75 mg and 150 mg dosage forms commenced in September 2025 and was completed in November 2025.  The high dose (300 mg) dosage form was launched in Europe in August 2026.  Omlyclo® to date remains the only omalizumab biosimilar approved in the EU, with Celltrion receiving EU market authorisation for its 75 mg/0.5 mL and 150 mg/1 mL PFS formulations in May 2024, and approval for the 300 mg formulation in November 2025

Omalizumab biosimilars in development include Kashiv BioSciences/Alvotech’s ADL-018/AVT23, with an application for ADL-018 accepted for review by Health Canada in June 2026 and marketing applications for AVT23 accepted by the UK’s MHRA in March 2025 and the European Medicines Agency in October 2025.  Under an exclusive licensing agreement with Kashiv entered in October 2023, Alvotech holds the commercialisation rights to ADL-018/AVT23 in Canada, together with the European Economic Area, UK, Switzerland, Australia and New Zealand.  Kashiv has entered into agreements for commercialisation of ADL-018 with Cristália for LATAM (August 2025) and MS Pharma for MENA markets (August 2025).

Teva’s biosimilar omalizumab applications have been accepted for review in the US and EU (March 2026) and CuraTeQ announced Phase 3 study results for its biosimilar omalizumab, BP11, in April 2026.  Mabpharm claims to have had an omalizumab biosimilar (Aomaishu®) approved for marketing in China in May 2023.

Alvotech and Lotte Biologics Enter into Strategic Partnership for Biosimilars

On 6 October 2026, Alvotech announced that it has entered into a strategic manufacturing partnership for biosimilars with Lotte Biologics. a contract development and manufacturing organisation (CDMO) that provides end-to-end services for complex pharmaceutical products.

Under the agreement, Lotte Biologics will manufacture multiple unidentified biosimilar products at its Syracuse facility in New York for global supply, with the potential to expand the collaboration over time.

Lotte’s Syracuse facility, which was acquired from BMS in January 2023, has 40,000 litres of bioreactor capacity for biologics manufacturing, supported by on-site process development and quality control capabilities.  According to Alvotech, the expansion of its global manufacturing network, including through the agreement with Lotte, will provide sufficient capacity to meet demand for its pipeline for the next ten years.

The agreement with Lotte follows FDA approval for Alvotech to manufacture its adalimumab biosimilar in a second production suite in Alvotech’s Reykjavik facility, effectively doubling its manufacturing capacity for the US market.

Kamada Launches Ustekinumab and Enoxaparin Biosimilars in Israel, Doubling its Biosimilar Portfolio

On 6 October 2026, Israel-headquartered biopharmaceutical company Kamada announced the launch of two new biosimilar products in Israel: Ustekinumab-Kamada, biosimilar to Janssen’s Stelara®, and Enoxaparin-Kamada, biosimilar to Sanofi’s Clexane®.

The launch of the two biosimilars has doubled Kamada’s biosimilar portfolio.  Kamada launched Bevacizumab-Kamada, biosimilar to Roche’s Avastin®, and Pegfilgrastim-Kamada, biosimilar to Amgen’s Neulasta®, in Israel over the last two years.  All four biosimilar products were approved and launched as interchangeable with the reference product.

According to Kamada, by 2030, it expects its biosimilar portfolio to include at least 12 marketed products in Israel and MENA, licensed from 6 different leading international biosimilar companies.

Both Janssen and Sanofi face significant competition globally from ustekinumab and enoxaparin biosimilars (respectively), including growing competition in MENA.  Notably, in December 2024, Formycon and MS Pharma announced that they have entered into a licence and supply agreement for commercialisation of Formycon’s ustekinumab biosimilar (FYB202) in MENA.  Earlier, in December 2022, Hikma Pharmaceuticals announced that it signed an exclusive licence agreement with Celltrion for its ustekinumab biosimilar (CT-P43), giving Hikma exclusive rights to market Celltrion’s product in all of Hikma’s MENA markets.

Orion and Qilu Partner on Biosimilar Pembrolizumab in EU

On 6 October 2026, Nordic-based Orion Pharma announced that it has entered into a European commercialisation agreement with China-headquartered Qilu Pharma, for Qilu’s intravenous QL2107, biosimilar to MSD’s Keytruda® (pembrolizumab).

Under the agreement, Orion has the exclusive right to distribute, market and sell Qilu’s biosimilar pembrolizumab in Europe, while Qilu will supply the product to Orion and is entitled to receive certain confidential development and regulatory milestone payments.

This follows the September 2026 announcement that Qilu has partnered with InvaGen Pharmaceuticals Inc., a wholly owned subsidiary of Cipla Limited, for the US commercialisation of QL2107 (pembrolizumab).

In January 2025, Qilu initiated a Phase 3 study for QL2107, to compare the efficacy and safety of QL2107 vs Keytruda® in combination with chemotherapy in treating metastatic non-squamous non-small-cell lung cancer.  The study has an estimated primary completion date of December 2026.

There are multiple pembrolizumab (IV) biosimilars approved or in development.  Samsung Bioepis and Celltrion each applied for Korean approval of their pembrolizumab biosimilars in August 2026 (SB27 and CT-P51, respectively).  In June 2026, Samsung Bioepis claimed to be the first developer of a pembrolizumab biosimilar to announce global phase 3 trial results.  Amgen also confirmed on 15 September 2026 that its Keytruda® biosimilar has successfully completed clinical trials with an FDA submission likely later this year.  Formycon announced successful Phase 1 results in February 2026, with its US commercialisation partner, Zydus, expressing optimism that it is well-placed to file the first BLA in the US for biosimilar pembrolizumab.

Pembrolizumab biosimilars have reportedly been launched in Paraguay (by Bioeticos in August 2025) and approved in Vietnam (by Biocad in November 2025) and Jordan (by Sana Pharma in February 2026).  Pembrolizumab biosimilars are also in clinical trials including by mAbxience, Sandoz, Bio-Thera, Shanghai Henlius, BioNTech and Enzene.

What Happens When a Patent Is Challenged? Free eBook

For organisations operating in pharmaceuticals, biotechnology, medical technology and agricultural sciences, intellectual property is often among their most valuable assets.

 

Years of research. Significant investment. Regulatory hurdles. Clinical or field trials. Product development. Commercialisation.

Much of this investment ultimately relies on the strength and enforceability of patent rights.

But what happens when those rights are challenged?

 

Would you know what options are available if a competitor launched a potentially infringing product?

Would you know how quickly Australian patent proceedings can move, or what steps can be taken to protect market position while a dispute is ongoing?

Could your business respond effectively if a patent covering a critical product, platform technology, biologic, diagnostic tool or agricultural innovation came under attack?

These are questions many organisations do not consider until a dispute has already emerged.

By then, the commercial stakes can be significant.

A patent dispute can affect product launches, market exclusivity, licensing opportunities, investment decisions and long-term commercial strategy.

For pharmaceutical companies, the consequences may extend even further. The outcome of litigation can influence pricing, reimbursement pathways and the timing of generic or biosimilar market entry.

For biotechnology, medical technology and agricultural businesses, a dispute may impact access to key technologies, breeding innovations, manufacturing processes, diagnostics, formulations or research partnerships.

Understanding the litigation landscape before a dispute arises is therefore not simply a legal exercise.

It is an important component of risk management and strategic planning.

Some questions businesses should consider include:

  • What happens when a patent infringement claim is filed in Australia?
  • How can competitors challenge the validity of a patent?
  • When might urgent court intervention be available?
  • What role do expert witnesses play in complex scientific disputes?
  • How does discovery work when technical information and confidential research are involved?
  • How long do patent proceedings typically take?
  • What strategic considerations can influence the outcome before a matter even reaches trial?
  • What unique issues arise in pharmaceutical and life sciences patent disputes?

The answers to these questions are rarely straightforward.

To help innovators, patent owners and life sciences businesses better understand the Australian patent litigation landscape, we have prepared our free e-book, Patent Litigation in Australia, which provides an overview of the key stages, procedures and strategic considerations involved in patent disputes, with a particular focus on pharmaceutical and life sciences matters.

Download the guide and gain a clearer understanding of what may be involved when innovation is put to the test.

 

 

Pearce IP can assist in Australia, New Zealand and internationally. Use our Contact Form or email us at info@pearceIP.law or call Australia Tel: +61 (0) 2 9023 9988 or New Zealand Tel: +64 (4) 886 1199.


 

About Pearce IP

Pearce IP is a privately owned/independent, specialist, life-sciences focussed, intellectual property/law firm offering lawyers and attorneys in Australia and New Zealand.

Our lawyers and attorneys specialise in pharma, biopharma, biotech, ag-tech, food-tech, med-tech, although our work is broader than these industries.

Pearce IP and its leaders are ranked in every notable legal directory including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, Best Law Firms, among others. In 2025, Pearce IP was honoured by Australasian Lawyer and New Zealand Lawyer as a Top Specialist Firm, 5 Star Employer of Choice, and the “Standout Winner” for Inclusion and Culture (<100 employees).  

Pearce IP is the only leading IP firm in Australia and New Zealand with a female founder, and is certified by WEConnect International as women owned.

 

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (Trans Tasman)

Naomi is the CEO and Founder of Pearce IP, and is one of ANZ’s leading IP practitioners. Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 29 years’ experience, and a background in molecular biology/biochemistry.

Ranked in virtually every notable legal directory, highly regarded by peers and clients, Naomi is renowned for her successful and elegant IP/legal strategies focussing on complex/multijurisdictional litigation, global FTO, and strategic advice.  Among other awards, Naomi is the 2026 Lexology Client Choice Winner for Patents, the 2024 Lawyers Weekly Women in Law “Executive of the Year”, the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Winner for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year”, and the 2021 Lawyers Weekly Women in Law “Partner of the Year”.  Ranked in Chambers Asia Pacific, Chambers Global,  IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks.

Pearce IP is the premier life sciences focussed firm in ANZ.  Commencing in 2017. Pearce IP is the 2025 Australasian Lawyer and NZ Lawyer 5-Star Employer of Choice & “Standout Winner” for Inclusion and Culture (<100 employees).  In 2021, Pearce IP was the Lawyers Weekly Australian Law Awards IP Team of the Year.

Helen Macpherson

Helen Macpherson

Executive, Lawyer (Head of Litigation –Australia)

Helen is a highly regarded intellectual property specialist and industry leader with more than 25 years’ experience advising on patents, plant breeder’s rights, trade marks, copyright and confidential information. She is known for her expertise in complex, high-value patent matters and leverages her technical background in biochemistry and molecular biology to work across a wide range of technologies, including inorganic, organic, physical and process chemistry, biochemistry, biotechnology (including genetics, molecular biology and virology), and physics. Helen is an active member of the Intellectual Property Committee of the Law Council of Australia and the Intellectual Property Society of Australia and New Zealand.

FDA Approves Additional Manufacturing Capacity for Alvotech’s Biosimilar Adalimumab

On 5 October 2026, Alvotech announced that the FDA has approved its supplement to the Biologics License Application for AVT02 (marketed as Simlandi® in the US), biosimilar to AbbVie’s Humira® (adalimumab). This approval allows drug manufacturing in a second production suite in Alvotech’s Reykjavik facility and will effectively double the manufacturing capacity available to support Alvotech’s biosimilar adalimumab supply in the US.

According to Alvotech, the FDA’s approval “further confirms” resolution of FDA inspection related matters at the Reykjavik site.  A July 2025 inspection had found deficiencies at the site, with the FDA then rejecting Alvotech’s golimumab (AVT05), aflibercept (AVT06), and denosumab (AVT03) BLAs in November 2025, December 2025 and January 2026, respectively.  After conducting a “remediation project” to address the FDA’s comments, Alvotech resubmitted its BLAs to the FDA in June 2026.  In July 2026, the FDA closed its inspection of the Reykjavik site with a Voluntary Action Indicated (VAI) classification (meaning objectionable conditions or practices were found, but the FDA did not take or recommend any administrative or regulatory action).

Alvotech expects the FDA to take action on its pending applications associated with the Reykjavik facility according to their respective goal dates, including for AVT16, biosimilar to Entyvio® (vedolizumab), which is currently the subject of pending BPCIA litigation.

Fresenius Completes Full Acquisition of mAbxience for ~€750 million

On 1 October 2026, Fresenius SE announced that it has completed its acquisition of Spanish-based mAbxience by acquiring the remaining 45% stake in the company, having taken a 55% majority stake in 2022.  The acquisition was completed for up to €750 million, including a contingent payment of €50 million upon site-approvals.

mAbxience’s biosimilar platform is now wholly owned within Fresenius Kabi’s biopharma business, creating a vertically integrated business covering the full value chain from development and manufacturing to commercialisation.

mAbxience’s biosimilars to Amgen’s Prolia® and Xgeva® (denosumab), were approved in the US in December 2025 (as Boncresa™ and Oziltus™) and in Europe in July 2025 (as Izamby® and Denbrayce®).  Last month, mAbxience entered into a licensing, development, manufacturing and commercialisation agreement with Sandoz for a biosimilar to Roche/Chugai’s Hemlibra® (emicizumab).

Celltrion’s Biosimilar Tocilizumab First to be PBS Listed in Australia

On 1 October 2026, Celltrion’s Avtozma® (tocilizumab), biosimilar to Genentech’s Actemra®, became the first tocilizumab biosimilar to be listed on Australia’s Schedule of Pharmaceutical Benefits (PBS).  The PBS listing of Avtozma® will result in a mandatory 25% statutory price reduction for Actemra®.

Avtozma® was the first, and remains the only, tocilizumab biosimilar to be approved in Australia (May 2025).  It was launched in Korea in June 2025. in the US (IV formulation) in October 2025, and in Europe in January 2026.  The biosimilar has also been granted marketing authorisation in a number of other regions, including Japan (September 2022) and New Zealand (December 2025).

Celltrion additionally had the following products listed on the PBS on 1 October 2026:

Samsung Bioepis and Teva Expand Strategic Partnership for up to Six Biosimilars, Including Benralizumab & Canakinumab

On 1 October 2026, Samsung Bioepis and Teva Pharmaceuticals announced a global collaboration and licence agreement to expand their existing partnership for up to six additional biosimilars.  The products covered by the agreement include SB44, biosimilar to Novartis’ Ilaris® (canakinumab), and SB41, biosimilar to AstraZeneca’s Fasenra® (benralizumab), plus four other undisclosed early-stage biosimilars.

Under the agreement, Samsung Bioepis is responsible for development, regulatory approval and manufacture, while Teva is responsible for commercialisation of the biosimilars in global markets including the US, Canada and Europe, with an option to expand the partnership to other territories.

Teva and Samsung Bioepis first entered into a strategic partnership in January 2025 for the US-commercialisation of Samsung Bioepis’ Epysqli® (eculizumab-aagh), biosimilar to Alexion’s Soliris®.  In July 2026, that agreement was expanded to include the commercialisation of Samsung Bioepis’ Opuviz® (aflibercept), biosimilar to Regeneron/Bayer’s Eylea®, in Canada.

No canakinumab biosimilars are reported to have been approved in major markets.  However, in May 2025, Alvotech and Advanz expanded their partnership to include the development and commercialisation of a canakinumab biosimilar in Europe.  Generium’s Limiris™ (canakinumab) was approved in Russia in September 2025, while it was reported in June 2026 that Belarusian company BioImmunity LLC obtained registration in Belarus of its canakinumab biosimilar and was seeking approval for the drug in Russia.

Benralizumab biosimilars are still in early development.  Enzene has a benralizumab biosimilar within its development pipeline.

MSD’s Subcutaneous Keytruda® Launched in South Korea

On 30 September 2026, Korea Biomedical Review reported that MSD has launched Keytruda SC™ (pembrolizumab and berahyaluronidase alfa) in Korea and will begin shipping product starting on 1 October 2026.

Keytruda SC™ received approval from Korea’s Ministry of Food and Drug Safety in May 2026 for 35 indications across 18 cancer types, including lung cancer, triple-negative breast cancer, gastric cancer and endometrial cancer.

MSD’s subcutaneous pembrolizumab has been approved in a number of countries, including in the US as Keytruda Qlex™ (September 2025); in the EU (November 2025), Canada (February 2026), and Australia (July 2026), as Keytruda SC™; and in Japan as Keyject™ (September 2026).

MSD is currently engaged in disputes with Halozyme in relation to Keytruda SC™, with Halozyme alleging that MSD is infringing various patents to Halozyme’s MDASE™ subcutaneous delivery technology, including:

While there are no reports of biosimilar subcutaneous pembrolizumab development to date, there are multiple pembrolizumab (IV) biosimilars approved or in development.  Samsung Bioepis and Celltrion each applied for Korean approval of their pembrolizumab biosimilars in August 2026 (SB27 and CT-P51, respectively).  In June 2026, Samsung Bioepis claimed to be the first developer of a pembrolizumab biosimilar to announce global phase 3 trial results.  Amgen also confirmed on 15 September 2026 that its Keytruda® biosimilar has successfully completed clinical trials with an FDA submission likely later this year.  Formycon announced successful Phase 1 results in February 2026, with its US commercialisation partner, Zydus, expressing optimism that it is well-placed to file the first BLA in the US for biosimilar pembrolizumab.

Pembrolizumab biosimilars have reportedly been launched in Paraguay (by Bioeticos in August 2025) and approved in Vietnam (by Biocad in November 2025) and Jordan (by Sana Pharma in February 2026).  Pembrolizumab biosimilars are also in clinical trials including by mAbxience, Sandoz, Bio-Thera, Shanghai Henlius, BioNTech, Qilu Pharmaceutical and Enzene.

Janssen Wins Preliminary Injunction Preventing Accord/Bio-Thera from Launching Biosimilar Golimumab in US

On 30 September 2026, the US District Court for the District of Delaware granted Janssen a preliminary injunction preventing Accord Biopharma and Bio-Thera Solutions from launching Immgolis™ and Immgolis Intri™ (BAT2506), biosimilars to Janssen’s Simponi® and Simponi Aria® (golimumab), in the US.  The reasons for the Court’s decision are not yet publicly available.

Accord and Bio-Thera have appealed the decision, with a Notice of Appeal filed on 1 October 2026.

Janssen originally commenced BPCIA proceedings against Accord and Bio-Thera on 3 March 2026, alleging that Accord/Bio-Thera’s (Immgolis™ and Immgolis Intri™ (BAT2506)) infringe 17 Janssen patents, relating to anti-TNF antibodies, manufacturing methods applicable to biologic drugs (including cell culture processes) and methods of treating ankylosing spondylitis and psoriatic arthritis with golimumab.

Janssen’s allegations regarding 4 method of treatment patents (11,014,982, 11,041,020, 12,122,824, 12,291,566) were subsequently dismissed by consent.  Accord and Bio-Thera filed petitions for inter partes review (IPR) of those 4 Janssen method of treatment patents on 20 March 2026 (IPR2026-00256, IPR2026-00257, IPR2026-00258, IPR2026-00259).  The IPRs were instituted by the Patent Trial and Appeal Board on 9 September 2026.

Janssen has also commenced BPCIA proceedings against Alvotech (19 June 2026), alleging Alvotech’s AVT05 (golimumab) infringes 14 patents.  Teva, Alvotech’s US commercialisation partner, was granted leave to intervene in the proceeding and has filed an application seeking a declaratory judgment of non-infringement and invalidity in relation to the 14 asserted patents.

Janssen filed a motion for preliminary injunction against Alvotech on 29 July 2026, arguing Alvotech infringes US 10,421,986, relating to a high cell density harvesting process.  The preliminary injunction hearing is to be scheduled for a date on or after 30 October 2026.

Immgolis™ and Immgolis Intri™ are the first and only golimumab biosimilars to have been FDA-approved (May 2026).  Alvotech resubmitted its BLA for AVT05 to the FDA in June 2026 after receiving a complete response letter in November 2025.

Pearce IP BioBlast® for the week ending 25 September 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®.  Significant biosimilar activities for the week ending 25 September 2026 are set out below:


Golimumab, Ustekinumab

On 16 September 2026, Fuji Pharma announced that it has obtained marketing approval in Japan for Golimumab BS 50 mg autoinjector for subcutaneous injection… Read more here.

Insulin efsitora alfa-gobe

On 24 September 2026, Eli Lilly announced that the FDA has approved Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection for treatment of… Read more here.

Ranibizumab

September 2026 has been a busy month for ranibizumab with two new registrations on the Australian Register of Therapeutic Goods (ARTG): Novartis’ Vurjor®… Read more here.
 
 
On 21 September 2026, Roche announced that the European Commission (EC) has approved Susvimo® (ranibizumab) as a 100 mg/mL solution for injection for the… Read more here.

Semaglutide

On 23 September 2026, Mylan filed a Complaint in the US District Court for the District of Delaware seeking a declaration of non-infringement and invalidity in relation… Read more here.

Biopharma Deals

On 24 September 2026, Nanexa announced that it has entered into an exclusive global licence and collaboration agreement with Novo Nordisk for the development of… Read more here.

About Pearce IP

Pearce IP is a privately owned/independent, specialist, life-sciences focussed, intellectual property/law firm offering lawyers and attorneys in Australia and New Zealand.

Our lawyers and attorneys specialise in pharma, biopharma, biotech, ag-tech, food-tech, med-tech, although our work is broader than these industries.

Pearce IP and its leaders are ranked in every notable legal directory including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, Best Law Firms, among others. In 2025, Pearce IP was honoured by Australasian Lawyer and New Zealand Lawyer as a Top Specialist Firm, 5 Star Employer of Choice, and the “Standout Winner” for Inclusion and Culture (<100 employees).  

Pearce IP is the only leading IP firm in Australia and New Zealand with a female founder, and is certified by WEConnect International as women owned.

 

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (Trans Tasman)

Naomi is the CEO and Founder of Pearce IP, and is one of ANZ’s leading IP practitioners. Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 29 years’ experience, and a background in molecular biology/biochemistry.

Ranked in virtually every notable legal directory, highly regarded by peers and clients, Naomi is renowned for her successful and elegant IP/legal strategies focussing on complex/multijurisdictional litigation, global FTO, and strategic advice.  Among other awards, Naomi is the 2026 Lexology Client Choice Winner for Patents, the 2024 Lawyers Weekly Women in Law “Executive of the Year”, the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Winner for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year”, and the 2021 Lawyers Weekly Women in Law “Partner of the Year”.  Ranked in Chambers Asia Pacific, Chambers Global,  IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks.

Pearce IP is the premier life sciences focussed firm in ANZ.  Commencing in 2017. Pearce IP is the 2025 Australasian Lawyer and NZ Lawyer 5-Star Employer of Choice & “Standout Winner” for Inclusion and Culture (<100 employees).  In 2021, Pearce IP was the Lawyers Weekly Australian Law Awards IP Team of the Year.

Chantal Savage

Chantal Savage

Special Counsel, Lawyer

Chantal is an intellectual property disputes lawyer with experience advising across the spectrum of IP rights, including patents, trade marks, copyright, plant breeder’s rights and trade secrets/confidential information. Recognised as a Rising Star in IP by the Legal 500 Asia Pacific (2021-2024), Chantal has previously worked for international and top tier law firms in Australia and the United Kingdom.

With a science degree specialising in molecular biology and biochemistry, Chantal’s practice focuses particularly on complex, high-value, multi-jurisdictional patent infringement and revocation proceedings for clients in the life sciences sectors.

Actor’s Biosimilar Aflibercept Approved in Australia

On 29 September 2026, the Australian Therapeutic Goods Administration (TGA) approved two aflibercept biosimilars sponsored by Actor Pharmaceuticals: Aflivu® and Ahzantive™.  Both brands are approved for all indications of the reference product, Regeneron/Bayer’s Eylea®, in 40 mg/mL solution for intravitreal injection vial and pre-filled syringe.

Actor entered into an exclusive licence agreement with Klinge Biopharma, the exclusive holder of the global commercialisation rights for Formycon’s FYB203 (aflibercept), in October 2025.  FYB203 is approved as Ahzantive® in the US (June 2024) and as Ahzantive® and Baiama® in Europe (January 2025).  Apotex commercialises an aflibercept biosimilar in Canada, under licence from Sam Chun Dang, under the brand name Aflivu® (approved June 2023, launched July 2025).

In August 2025, Actor commenced proceedings against Regeneron and Bayer in the Federal Court of Australia, seeking to invalidate Regeneron’s patent AU 2012205599 relating to methods of treatment using aflibercept.  Regeneron/Bayer cross-claimed for infringement.  However, those proceedings were discontinued by consent on 18 March 2026.

Actor’s aflibercept biosimilars join Celltrion’s Eydenzelt® (approved March 2025), Sandoz’s Afqlir® and Enzeevu® (approved May 2025) and Samsung Bioepis’ Opuviz® (approved September 2025), on the Australian Register of Therapeutic Goods.  Sandoz’s Afqlir® is currently the only biosimilar aflibercept listed on Australia’s Schedule of Pharmaceutical Benefits (PBS) (February 2026), although Celltrion’s Eydenzelt® was recommended for PBS listing in August 2026.

In November 2025, Regeneron/Bayer and Sandoz settled Australian aflibercept patent infringement/revocation proceedings on confidential terms.  The settlement followed the Australian Federal Court’s refusal to grant Regeneron/Bayer a preliminary injunction preventing the launch of Sandoz’s biosimilar aflibercept.

STADA and Sino Biopharmaceutical Enter into Exclusive Partnership for up to Four Biosimilars, Including to MSD’s Keytruda® (Pembrolizumab)

On 28 September 2026, STADA announced that it has entered into an exclusive partnership with Chia Tai Tianqing Pharmaceutical Group (CTTQ), a subsidiary of Sino Biopharmaceutical Limited, for up to four biosimilars. This includes CTTQ’s TQB3570, biosimilar to MSD’s Keytruda® (pembrolizumab), with an option for STADA to add up to three further immunology and oncology biosimilars.

Under the agreement, China-headquartered CTTQ is responsible for development, manufacture and supply, and STADA is responsible for marketing authorisations and exclusive commercialisation in the EU, Switzerland, UK and Commonwealth of Independent States, with options for the US and Gulf Cooperation Council member states.  The specific financial terms of the partnership have not been disclosed.

Competition is heating up in relation to the first pembrolizumab biosimilar to be approved in major markets.  Applications for approval of pembrolizumab biosimilars were filed in Korea by Samsung Bioepis (SB27) and Celltrion (CT-P51) in August 2026.  Two months earlier, in June 2026, Samsung Bioepis claimed to be the first developer of a pembrolizumab biosimilar to announce global phase 3 trial results.  Amgen also confirmed on 15 September 2026 that its Keytruda® biosimilar has successfully completed clinical trials with an FDA submission likely later this year.

Formycon has been taking a streamlined clinical development approach in relation to its pembrolizumab biosimilar, FYB206, announcing successful Phase 1 results in February 2026, with its US commercialisation partner, Zydus, expressing optimism that it is well-placed to file the first BLA in the US for biosimilar pembrolizumab.

Pembrolizumab biosimilars have reportedly been launched in Paraguay (by Bioeticos in August 2025) and approved in Vietnam (by Biocad in November 2025) and Jordan (by Sana Pharma in February 2026).  Pembrolizumab biosimilars are also in clinical trials including by mAbxience, Sandoz, Bio-Thera, Shanghai Henlius, BioNTech, Qilu Pharmaceutical and Enzene.

Teva’s Second Denosumab Biosimilar FDA-Approved

On 28 September 2026, Teva announced that it has strengthened its position in the biosimilars market with the FDA approval of its internally developed Degevma™ (denosumab-adet), biosimilar to Amgen’s Xgeva®.  Degevma™ is indicated for all approved reference indications and will be available as a 120mg/1.7mL solution for injection in a vial.

Teva’s biosimilar to Amgen’s Prolia® (denosumab) was approved in March 2026 as Ponlimsi™.  Both Degevma™ and Ponlimsi™ are anticipated to be launched in the US “in the coming months”.  The biosimilars were approved in the EU in November 2025.

The US has a highly competitive denosumab biosimilar market with numerous denosumab biosimilars already launched, including Sandoz’s Jubbonti® and Wyost® (approved March 2024, launched June 2025), Celltrion’s Stoboclo® and Osenvelt® (approved March 2025, launched July 2025), Fresenius Kabi’s Conexxence® and Bomyntra® (approved March 2025, launched July 2025), Shanghai Henlius/Organon’s Bildyos® and Bilprevda® (approved September 2025, launched October 2025), Biocon’s Bosaya™ and Aukelso™ (approved September 2025, launched October 2025), Gedeon Richter/Hikma’s Enoby™ and Xtrenbo™ (approved September 2025, launched January 2026), and Accord BioPharma’s Osvyrti® and Jubereq® (approved November 2025, launched July 2026).

Sandoz Announces Opening of its High-Volume Biosimilar Production Centre in Slovenia

On 29 September 2026, Sandoz announced the opening of its new high-volume biosimilar drug substance manufacturing centre in Lendava, Slovenia.  The opening is a step towards Sandoz’s recently announced Bio100 goal to have more than 100 biosimilars in its portfolio by 2040.

The Lendava biosimilar drug substance centre will utilise smart automation and process analytical technology to support high-volume drug manufacturing.  The technology will be used throughout development through to full-scale drug manufacturing processes.

This is Sandoz’s second major biosimilar facility completed in Slovenia this year, following the opening of its biosimilar development centre in Ljubljana in June 2026.  In September 2026, Sandoz also announced plans to build a new biosimilar drug manufacturing facility in Ljubljana, to be located next to the biosimilar development centre.  The project will involve a US $300 million investment in disposable fed-batch technology to expand Sandoz’s in-house manufacturing capacity and strengthen end-to-end biosimilar development and manufacturing in Europe.

Novo Nordisk Enters Into EUR 1.165B Deal with Nanexa for Long-Acting Diabetes & Weight Loss Injectables

On 24 September 2026, Nanexa announced that it has entered into an exclusive global licence and collaboration agreement with Novo Nordisk for the development of long-acting injectable formulations of Novo Nordisk’s products using Nanexa’s PharmaShell® drug delivery platform.  The Novo products to be developed have not been disclosed but will target type 2 diabetes, obesity and other cardiometabolic diseases.

Under the agreement, Denmark-based Novo will receive a global licence to use Sweden-based Nanexa’s PharmaShell® technology platform for up to five development programs.  The long-acting injectable formulations will be developed with monthly and quarterly frequency administration targets.

Nanexa will receive EUR615 million for upfront, development and regulatory milestones.  It is eligible to receive an additional EUR550 million subject to sales milestones, making the total value of the deal up to EUR1.165 billion.  Additionally, Nanexa is eligible to receive low single-digit royalties on global net sales of products developed under the agreement.

Nanexa’s PharmaShell® technology involves encapsulation of an active pharmaceutical ingredient with an ultra-thin coating using Atomic Layer Deposition.  The coating can be tailored to achieve precise, controlled and sustained release of the active pharmaceutical ingredient.

In December 2025, Nanexa entered into a licence and option agreement with Moderna for the use of its PharmaShell® technology for a selected compound, with options for up to four additional compounds.  Nanexa received an upfront payment of USD3 million, with up to USD500 million in potential milestone payments, as well as tiered single-digit royalties on future product sales.

FDA Approves Eli Lilly’s Once Weekly Insulin (Onswik™) for Type 2 Diabetes

On 24 September 2026, Eli Lilly announced that the FDA has approved Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection for treatment of type 2 diabetes in adults.  It is indicated for use as an adjunct to diet and exercise to control high blood sugar and will be available in a KwikPen® (500 units/mL and 1000 units/mL) “in the coming months”.

The FDA approval was based on positive results from the QWINT Phase 3 trials.  The trials evaluated the safety and efficacy of once-weekly Onswik™ in over 3400 patients across four studies (QWINT-1, QWINT-2, QWINT-3 and QWINT-4).  In each QWINT trial, Onswik™ met the primary endpoint of non-inferior A1C reduction from baseline that was comparable to Sanofi’s Lantus® (insulin glargine) or Novo Nordisk’s Tresiba® (insulin degludec).

According to Eli Lilly, the US approval for Onswik™ follows positive regulatory action in Europe (CHMP recommendation in June 2026), Japan (PMDA approved in September 2026) and Mexico.

Onswik™ is the second once-weekly basal insulin approved by the FDA.  Novo Nordisk’s Awiqli® (insulin icodec-abae) injection was the first once-weekly basal insulin for adults with type 2 diabetes to receive FDA approval (March 2026).  It was launched in August 2026 as a pre-filled pen (700 units/mL).

Mylan Challenges Novo Nordisk Patent in US Generic Wegovy® (Semaglutide) Dispute

On 23 September 2026, Mylan filed a Complaint in the US District Court for the District of Delaware seeking a declaration of non-infringement and invalidity in relation to Novo Nordisk’s U.S. Patent No. 12,551,536.  The patent was granted on 17 February 2026 and relates to a method for reducing body weight by subcutaneous administration of 2-10 mg semaglutide weekly.

Mylan has filed an abbreviated new drug application (ANDA) with the FDA (on an unidentified date) seeking approval to market semaglutide prefilled single dose pens.  In its Complaint, Mylan alleges that it has a reasonable apprehension that Novo Nordisk will sue Mylan for infringement of the US ‘536 patent.   This is on the basis that the US ‘536 patent is listed in the Orange Book for Wegovy®, but Novo Nordisk did not initiate litigation concerning that patent within 45 days of receiving Mylan’s notice that it believes no valid claim of the US 536 patent will be infringed by exploitation of its generic semaglutide product.

Mylan claims the US ‘536 patent is invalid on a number of grounds, including lack of novelty and obviousness and asks the Court to declare that the exploitation of Mylan’s generic semaglutide products will not infringe the ‘536 patent.

Novo Nordisk has previously sued Mylan for infringement of a number of US semaglutide patents, including in 2023 (five patents, including US 9,764,003), 2024 (US 12,029,779) and 2025 (US 12,214,017).  On 22 July 2025, the US District Court in Delaware ruled on the pleadings that Mylan did not induce infringement of the US ‘003 method of treatment patent in connection with its generic Wegovy® products.

Novo Nordisk has US patent infringement litigation pending against a number of other companies, including Apotex, Cipla and Sun Pharma, in relation to their generic semaglutide products.

Apotex received the first US FDA Tentative Approval for its generic semaglutide ANDA in April 2026, giving it an opportunity to be one of the first to launch generic Ozempic® in the US following expiry of Novo Nordisk’s exclusivity/patents.

Pearce IP BioBlast® for the week ending 18 September 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®.  Significant biosimilar activities for the week ending 18 September 2026 are set out below:


Emicizumab

On 18 September 2026, Sandoz and mAbxience announced they have entered a licensing, development, manufacturing and commercialisation agreement in relation… Read more here.

Etanercept

In a judgment published on 15 September 2026 (but delivered on 27 August 2026), the Federal Court of Australia found that Pfizer had failed to establish that Samsung… Read more here.

Gerfurliumab, Denecimig, Pembrolizumab, Ocrelizumab

On 18 September 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) announced the outcomes of its September 2026… Read more here.

Golimumab

On 16 September 2026, Teva filed an application seeking declaratory judgment of non-infringement and invalidity in relation to 14 Janssen patents asserted against… Read more here.

Infliximab

On 15 September 2026, Celltrion announced that it has filed an Investigational New Drug (IND) application with the FDA for a Phase 4 clinical trial of high-dose… Read more here.

Nivolumab

During a presentation on 15 September 2026, Amgen confirmed that it has filed an abbreviated Biologics License Application (aBLA) with the FDA for a biosimilar… Read more here.

 

On 15 September 2026, The Economic Times reported that Dr Reddy’s has launched Nivorz™, biosimilar to BMS’ Opdivo® (nivolumab), in India.  Nivorz™ will be… Read more here.

Omalizumab, Pertuzumab

On 18 September 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) announced the outcomes of its September… Read more here.

Pembrolizumab

On 16 September 2026, MSD’s subcutaneous pembrolizumab was approved in Japan under the name Keyject™.  Keyject™ (pembrolizumab and berahyaluronidase alfa)… Read more here.

 

As previously reported, since November 2024, MSD has filed a number of petitions for review with the US Patent Trial and Appeal Board (PTAB) challenging the validity… Read more here.

Pembrolizumab, Nivolumab

On 17 September 2026, India-based contract development and manufacturing organisation (CDMO) Shilpa Biologicals announced that it has signed an exclusive licence… Read more here.

Semaglutide

On 18 September 2026, Sandoz announced that Health Canada has approved Sandoz® Semaglutide, a generic version of Novo Nordisk’s Ozempic® (semaglutide)… Read more here.

Trastuzumab deruxtecan, Datopotamab deruxtecan

On 16 September 2026, Daiichi Sankyo announced that Japan’s Ministry of Health, Labour and Welfare has approved Enhertu® (trastuzumab deruxtecan) and Datroway®… Read more here.

Biopharma News

On 21 September 2026, Sandoz Group AG joined the Swiss Market Index (SMI), Switzerland’s leading blue-chip equity index.  The milestone was foreshadowed in an… Read more here.

About Pearce IP

Pearce IP is a privately owned/independent, specialist, life-sciences focussed, intellectual property/law firm offering lawyers and attorneys in Australia and New Zealand.

Our lawyers and attorneys specialise in pharma, biopharma, biotech, ag-tech, food-tech, med-tech, although our work is broader than these industries.

Pearce IP and its leaders are ranked in every notable legal directory including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, Best Law Firms, among others. In 2025, Pearce IP was honoured by Australasian Lawyer and New Zealand Lawyer as a Top Specialist Firm, 5 Star Employer of Choice, and the “Standout Winner” for Inclusion and Culture (<100 employees).  

Pearce IP is the only leading IP firm in Australia and New Zealand with a female founder, and is certified by WEConnect International as women owned.

 

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (Trans Tasman)

Naomi is the CEO and Founder of Pearce IP, and is one of ANZ’s leading IP practitioners. Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 29 years’ experience, and a background in molecular biology/biochemistry.

Ranked in virtually every notable legal directory, highly regarded by peers and clients, Naomi is renowned for her successful and elegant IP/legal strategies focussing on complex/multijurisdictional litigation, global FTO, and strategic advice.  Among other awards, Naomi is the 2026 Lexology Client Choice Winner for Patents, the 2024 Lawyers Weekly Women in Law “Executive of the Year”, the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Winner for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year”, and the 2021 Lawyers Weekly Women in Law “Partner of the Year”.  Ranked in Chambers Asia Pacific, Chambers Global,  IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks.

Pearce IP is the premier life sciences focussed firm in ANZ.  Commencing in 2017. Pearce IP is the 2025 Australasian Lawyer and NZ Lawyer 5-Star Employer of Choice & “Standout Winner” for Inclusion and Culture (<100 employees).  In 2021, Pearce IP was the Lawyers Weekly Australian Law Awards IP Team of the Year.

Chantal Savage

Chantal Savage

Special Counsel, Lawyer

Chantal is an intellectual property disputes lawyer with experience advising across the spectrum of IP rights, including patents, trade marks, copyright, plant breeder’s rights and trade secrets/confidential information. Recognised as a Rising Star in IP by the Legal 500 Asia Pacific (2021-2024), Chantal has previously worked for international and top tier law firms in Australia and the United Kingdom.

With a science degree specialising in molecular biology and biochemistry, Chantal’s practice focuses particularly on complex, high-value, multi-jurisdictional patent infringement and revocation proceedings for clients in the life sciences sectors.

Sandoz Begins Trading on Swiss Market Index

On 21 September 2026, Sandoz Group AG joined the Swiss Market Index (SMI), Switzerland’s leading blue-chip equity index.  The milestone was foreshadowed in an announcement by Sandoz on 9 July 2026 and comes less than three years after Sandoz became an independent publicly listed company.

The SMI comprises the 20 largest and most liquid stocks listed on the SIX Swiss Exchange and is widely regarded as the benchmark index for Swiss equities.  Other pharmaceutical companies on the SMI are Novartis AG and Roche Holding AG.  Dermatology focussed company, Galderma, also began trading on the SMI on 21 September 2026.

Sandoz recently announced that it is aiming to establish a portfolio of more than 100 biosimilars by 2040 as part of its Bio100 plan to maximise value in the “golden decade” for biosimilars.

Roche’s Susvimo® (Ranibizumab) Approved in EU

On 21 September 2026, Roche announced that the European Commission (EC) has approved Susvimo® (ranibizumab) as a 100 mg/mL solution for injection for the treatment of neovascular age-related macular degeneration (nAMD).

The European approval follows the CHMP’s positive opinion for Susvimo® in July 2026.  Susvimo® is delivered via an ocular implant, marketed as Contivue® in the EU, for continuous release into the vitreous of the eye.  The Contivue® devices include a refillable implant surgically inserted into the eye during a one-time, outpatient procedure.  Contivue® also includes four ancillary devices to initially fill, insert, refill, and remove the implant

Susvimo® was approved in the US for nAMD in July 2024, diabetic macular oedema in February 2025 and diabetic retinopathy in May 2025.  In the US, the devices and medicine (ranibizumab) are approved as a single product.

The US approvals followed an update and relaunch of the product, after Roche conducted a voluntary recall of the initial version (FDA approved in October 2021) as a result of test results showing some implants did not perform to Roche’s standards.

BioBlast® Editor and Contributing Author

Naomi Pearce & Emily Bristow

Naomi Pearce & Emily Bristow

Editor: Naomi Pearce, Executive Lawyer, Patent Attorney & Trade Mark Attorney
Contributing Author: Emily Bristow, Law Graduate

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.